Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)"

对“Nivolumab辅助化疗放疗治疗局限性肌层浸润性尿路上皮癌：一项多中心、单臂、II期、研究者发起试验（NEXT）的主要分析”的评论